GlassScriptPhysician profile
Carly D Rose
NPI 1639510449
$203,432.50
in general payments reported to CMS, 2019-2025
21 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $6,961 · 2021: $3,064 · 2022: $98K · 2023: $54K · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Food and Beverage: $9,244 · Consulting Fee: $7,225 · Travel and Lodging: $6,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,910.00 |
| Food and Beverage | $9,244.45 |
| Consulting Fee | $7,225.00 |
| Travel and Lodging | $6,641.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $110,139.82 | 2019-2025 | Cequa |
| Lumenis Be INC | $39,647.99 | 2022-2025 | Optilight |
| Oyster Point Pharma, INC. | $31,070.19 | 2022-2024 | Tyrvaya |
| Lumenis, INC | $5,775.02 | 2020-2021 | |
| Lumenis (Germany) Gmbh | $5,582.76 | 2022 | |
| Coopervision INC. | $2,900.71 | 2020-2023 | Myday Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $2,107.65 | 2021-2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $1,517.47 | 2019-2022 | |
| Harrow Eye, LLC | $1,416.87 | 2024 | Vevye |
| Tearlab Corp | $1,346.03 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $868.21 | 2019-2025 | |
| Alcon Vision LLC | $299.53 | 2019-2025 | Tryptyr, Dailies Total1, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $250.00 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $102.58 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $101.23 | 2024-2025 | Xdemvy |
| Valley Contax, INC. | $60.00 | 2020 | |
| Biotissue Holdings INC. | $58.21 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $23.31 | 2024 | Miebo, Xiidra |
| Allergan, INC. | $22.67 | 2021 | |
| Shire North American Group INC | $17.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.